Non-monoaminergic approaches in search of novel antidepressants

Clinical Neuropsychiatry

Volumn 9, Issue 4, 2012, Pages 182-183

  Catena Dell'Osso, Mario ^a   Marazziti, Donatella ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; IPRONIAZID; MONOAMINE OXIDASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MONOAMINERGIC SYSTEM; NEUROTRANSMISSION; NOTE; PATHOPHYSIOLOGY; QUALITY OF LIFE; RISK REDUCTION;

EID: 84870385061     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Catena-Dell'Osso M, Bellantuono C, Consoli G, Baroni S, Rotella F, Marazziti D (2011). Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 18, 245-255.
2. Kinney GG, Taber MT, Gribkoff VK (2000). The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol Neurobiol 21, 3, 137-152.
3. Lopez AD, Murray CC (1998). The global burden of disease, 1990-2020. Nature Med. 4, 11, 1241-1243.
4. Marazziti D, Catena-Dell'Osso M (2008). The role of oxytocin in neuropsychiatric disorders. Curr Med Chem 15, 7, 698-704.
5. Marazziti D, Catena Dell'Osso M, Consoli G, Baroni S (2009). Second messenger modulation: a novel target of future antidepressants? Curr Med Chem 16, 4679-4690.
6. Murray CJL, Lopez AD (1996). Evidence-based health policy-lessons from the global burden of disease study. Science 274, 5288, 740-743.
7. Paschos KA, Veletza S, Chatzaki E (2009). Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression. CNS Drugs 23, 9, 755-772.
8. rd ed. Cambridge University Press, Cambridge.
9. World Health Organization. Data and Statistics. www.who.int/research/en. Accessed September 16, 2010.
10. Zarate Jr. C, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G (2010). Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 18, 5, 293-303.